The mission of NNECOS is to promote the highest quality care for patients with cancer and blood disorders in our region through professional networking, education, and scientific research, as well as patient advocacy and public policy.

FEATURED SPRING SESSIONS

Lunchtime Best Oncology Practice Series

Upcoming Topics:

  • 3/28/24 - Patient-Centered Communication - presented by Lilly
  • 4/25/24 - Empathy in Action: Integrating Emotional Responsiveness into Advance Care Planning Across Healthcare Disciplines - Hilary Carroll McGuire, DNP, FNP-BC, ACHPN
  • 5/30/24 - Social Determinants of Health - presented by Takeda 
  • 6/27/24 - Exercise to help with Fatigue - Jenny Spencer, BSN, RN, OCN

New Job Posted - NNECOS Classifieds

  • Dartmouth Cancer Center - NP or Physician Assistant - Per Diem

  • Dartmouth Cancer Center - NP or Physician Assistant

  • Dartmouth Cancer Center - Hematology Advanced Practice Provider

  • UVM Cancer Center - Faculty Scientist

  • UVM Cancer Center - 

    Medical oncologist/hematologist faculty member on the Clinical 

    Scholar Pathway at the Assistant/Associate level
  • UVM Cancer Center - 

    Physician-scientist/academic clinician to serve as Associate Director of Clinical &

    Translational Research.

  • Beth Israel Lahey Health Exeter -

    Experienced Hematology/Oncology Physician.
  • UVM Medical Center - Clinical Program Coordinator - Hematology 

eDUCATIONAL PROGRAM GRANTS

Learn more about our unique funding program

Latest FDA Approvals And Drug-Related Updates

Latest FDA Approvals

  • February 16 - FDA approves osimertinib with chemotherapy for EGFR-mutated non-small cell lung cancer | FDA
  • February 16 - FDA grants accelerated approval to lifileucel for unresectable or metastatic melanoma | FDA
  • February 15 - FDA approves tepotinib for metastatic non-small cell lung cancer
  • February 13 - FDA approves irinotecan liposome for first-line treatment of metastatic pancreatic adenocarcinoma
  • January 19 - FDA approves erdafitinib for locally advanced or metastatic urothelial carcinoma
  • January 12 - FDA approves pembrolizumab with chemoradiotherapy for FIGO 2014 Stage III-IVA cervical cancer
  • December 15 - FDA approves enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial cancer
  • December 14 - FDA approves belzutifan for advanced renal cell carcinoma
  • December 13 - FDA approves eflornithine for adult and pediatric patients with high-risk neuroblastoma
  • December 1 -FDA grants accelerated approval to pirtobrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma 
  • November 27 -FDA grants accelerated approval to pirtobrutinib for chronic lymphocytic leukemia and small lymphocytic lymphomaFDA approves nirogacestat for desmoid tumors 
  • November 16 - FDA approves capivasertib with fulvestrant for breast cancer
  • November 16 - FDA approves enzalutamide for non-metastatic castration-sensitive prostate cancer with biochemical recurrence
  • November 16 - FDA approves pembrolizumab with chemotherapy for HER2-negative gastric or gastroesophageal junction adenocarcinoma | FDA
  • November 15 - FDA approves repotrectinib for ROS1-positive non-small cell lung cancer | FDA

Package/Label Updates

  • August - FDA approves new indication for  anemia without previous erythropoiesis stimulating agent use (ESAna├»ve) in adult patients with very low-to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions

    Code Updates

    • Effective for dates of service on or after April 1, 2024, the Centers for Medicare and Medicaid Services (CMS) has assigned the following Healthcare Common Procedure Coding System (HCPCS)* J-Code for ELREXFIO (elranatamab-bccm) injection:
    J1323- Injection, elranatamab-bcmm, 1 mg

    Other Updates


    Business of Oncology Practice

    Missed this series? Recording available

    Looking Back!

    Enjoy this wonderful interview with 3 of NNECOS' founding members!



    Get Involved with a NNECOS Task Force


    SOCIAL MEDIA

     

    Thank You Corporate Members!


    Group Practice Members

    Because your entire team benefits
    from being a part of NNECOS!

    Regional Educational Programs

    • Bristol Myers Squibb Specialty pharmacy webinar series.

    www.nnecos.org/regional

    Special thanks to our 2024 Diamond & Platinum Corporate Members!



       


     

     

     
     


    Platinum Members




     




     
       


         


         

    View the complete list of corporate members.




    Northern New England Clinical Oncology Society
    P.O. Box 643
    Sandown, NH 03873-0643
    Telephone (603) 887-1948
    info@nnecos.org

    This website brought to you by:


    Powered by Wild Apricot Membership Software